当前位置： SCI文献检索 > MOLECULAR IMAGING AND BIOLOGY期刊下所有文献 > (2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.

(2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.

Abstract：

PURPOSE:Previous reports confirmed that (2S,4R)-4-[18F]Fluoroglutamine ([18F]GLN) accumulated in bone and bone marrow. This study investigates the potential of using [18F]GLN positron emission tomography (PET) to monitor changes of bone marrow activity after chemotherapy (myelosuppression). PROCEDURES:Bone marrow inhibition model in mice was induced by an intravenous injection of chemotherapy drug (doxorubicin or rituximab) and the inhibition was confirmed by routine blood cell counts. Bone uptakes of these four radiotracers (2-deoxy-2-[18F]fluoro-D-glucose, [18F]GLN, 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT), and sodium [18F]fluoride) in the mice were measured after i.v. injection and dissection of femur and tibia, and the uptakes in bone-only (BO) and bone marrow (BM) were obtained after separating bone from bone marrow. Additionally, six volunteers were recruited and evaluated with [18F]GLN. The PET-/CT-guided volumes of interests (VOI) in cervical, thoracic, lumbar vertebra, and skull cortical bone were defined as bone marrow or bone for evaluation, respectively. RESULTS:[18F]GLN showed a relatively high bone marrow uptake in mice (up to 9.5 ± 1.3 % ID/g) at 1 h after injection, which was 2.1 times that of [18F]FLT. The [18F]GLN uptakes in the bone marrow were substantially inhibited by chemotherapy drug. The decrease of [18F]GLN's bone marrow uptake was consistent with the reduction of white blood cells (myelosuppression). For [18F]GLN/PET imaging in humans, the SUVmean value of bone marrow (1 h after i.v. injection) was between 3.1 and 3.6 in the healthy volunteers (n = 3), and between 1.8 and 2.2 (n = 3) (P < 0.001) in myelosuppression patients, showing a clear reduction of bone marrow uptake. CONCLUSIONS:Dissection experiments in mice showed that [18F]GLN displayed relatively high bone marrow uptake, and the uptake was sensitive to bone marrow inhibition induced by doxorubicin/rituximab. The same conclusion was confirmed [18F]GLN/PET imaging in humans. Therefore, [18F]GLN/PET imaging may be a useful tool to assess reduction of bone marrow activity in cancer patients, who may be at risk of myelosuppression after chemotherapy. TRIAL REGISTRATION:Approved by Institutional Review Board of Peking University Cancer Hospital (No. 2017KT38). Registered 18 August 2017.

journal_name

Mol Imaging Biol

journal_title

Molecular imaging and biology

authors

Zhu H,Liu F,Zhang Y,Yang J,Xu X,Guo X,Liu T,Li N,Zhu L,Kung HF,Yang Z

doi

10.1007/s11307-019-01319-4

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

945-953

issue

eissn

1536-1632

issn

1860-2002

pii

10.1007/s11307-019-01319-4

journal_volume

pub_type

杂志文章

在线工具

(2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.